476 related articles for article (PubMed ID: 29649743)
1. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
Wu X; Wang Q; Li W
Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
[TBL] [Abstract][Full Text] [Related]
4. Discovery of small molecule inhibitors that interact with γ-tubulin.
Friesen DE; Barakat KH; Semenchenko V; Perez-Pineiro R; Fenske BW; Mane J; Wishart DS; Tuszynski JA
Chem Biol Drug Des; 2012 May; 79(5):639-52. PubMed ID: 22268380
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
[TBL] [Abstract][Full Text] [Related]
6. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
7. Butterfly Structure: A Privileged Scaffold Targeting Tubulin-Colchicine Binding Site.
Wang Y; Yao Y; Zhu HL; Duan Y
Curr Top Med Chem; 2020; 20(17):1505-1508. PubMed ID: 32543362
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
9. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
Dong M; Liu F; Zhou H; Zhai S; Yan B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
[TBL] [Abstract][Full Text] [Related]
10. New ligands of the tubulin colchicine site based on X-ray structures.
Álvarez R; Medarde M; Peláez R
Curr Top Med Chem; 2014; 14(20):2231-52. PubMed ID: 25434358
[TBL] [Abstract][Full Text] [Related]
11. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
12. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
Li W; Sun H; Xu S; Zhu Z; Xu J
Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
[TBL] [Abstract][Full Text] [Related]
13. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
15. Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019.
Xia LY; Zhang YL; Yang R; Wang ZC; Lu YD; Wang BZ; Zhu HL
Curr Med Chem; 2020; 27(40):6787-6814. PubMed ID: 31580244
[TBL] [Abstract][Full Text] [Related]
16. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
18. Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin.
Tyagi C; Gupta A; Goyal S; Dhanjal J; Grover A
BMC Genomics; 2014; 15 Suppl 9(Suppl 9):S3. PubMed ID: 25521775
[TBL] [Abstract][Full Text] [Related]
19. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
20. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
